Mike Doustdar

We have seen this company for a long time and we like what we have seen.

OK.

You're going to London, I think, tomorrow, right?

Possibly.

OK.

Are you going to the States after that?

I'm looking at the whole world.

So I'm going to go everywhere.

So the rumor is that basically you're going to be in the White House on Thursday.

And you're going to tell me that the deal's not done with the Trump administration on pricing.

And I'm going to ask you, how close are you, therefore, to a deal?

I'm going to say that we are very much aligned with the purpose of the negotiations and the discussions we're having with the administration.

We both would like to provide access to many more patients out there, affordable access.

Are you close?

So we are discussing very closely.

Okay.

Okay, closely.

One of the parts of the discussion...

I'm assuming has to be about what is happening with copycats, about the companies that are producing drugs that were allowed when there were shortages, but now are using loopholes to maybe continue to produce products.

And I'm wondering whether or not a deal with the White House would include maybe closing some of those loopholes.